Simulations Plus reported a 9% increase in total revenue in Q3 2023, driven by its software segment. However, declining gross margins and rising operational costs could impact future profitability.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and ...

Simulations Plus SLP recently announced that the FDA (United States Food and Drug Administration) has renewed its DILIsym software licenses for the seventh year in a row. DILIsym is a modernized ...

“Our software updates reflect the needs our customers communicate to us, and GastroPlus 9.9 is no exception,” said Neil Miller, Vice President of Simulation Sciences at Simulations Plus. “We ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and ...

CEO Shawn O’Connor highlighted a 23% year-over-year revenue increase, with 5% organic growth, driven by the Adaptive Learning & Insights (ALI) and Medical Communication (MC) business units. Adjusted ...

While modeling and simulation software provider Simulations Plus (NASDAQ: SLP) reported mixed results for the fourth quarter of fiscal 2025, the company's outlook for fiscal 2026 was enough to propel ...

Medical tech company Simulations Plus (NASDAQ: SLP) ended up slightly in positive territory on Friday. That was largely due to solid quarterly results, although a bottom-line guidance cut dampened ...

Earnings call Simulations Plus delivered Q2 revenue of $24.3M, up 8% YoY, exceeding top-line guidance with strong software and services growth. Adjusted EBITDA margin reached 36%, and management ...

Simulations Plus has announced a collaboration with Nvidia aimed at speeding up drug development by combining advanced simulation software with GPU-powered computing and artificial intelligence tools.

Simulations Plus (SLP) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.10 per share a year ago. These ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...